Status:
UNKNOWN
Prevalence of Liver Fibrosis and Progression of Liver Fibrosis
Lead Sponsor:
Helen Kovari-Kramer
Collaborating Sponsors:
Swiss HIV Cohort Study
Conditions:
HIV Infection and Chronic Alanine Aminotransferase Elevation
Eligibility:
All Genders
18+ years
Brief Summary
Little is known about the clinical significance of chronic alanine aminotransferase (ALT) elevation in HIV-infected patients without hepatitis B and C coinfection. Study aim is first to evaluate the p...
Eligibility Criteria
Inclusion
- Inclusion criteria: Case patients:
- HIV-1 infection
- no hepatitis B and C coinfection
- chronic alanine aminotransferase (ALT) elevation after 1.1.2007
- signed informed consent
- no other common cause of liver disease
- Control patients:
- HIV-infection
- no hepatitis B and C coinfection
- no ALT elevation after 1.1.2002, the date when ALT values were regularly collected in the Swiss HIV Cohort Study (SHCS)
- no known chronic liver disease
- Exclusion criteria: please see inclusion criteria
Exclusion
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2018
Estimated Enrollment :
195 Patients enrolled
Trial Details
Trial ID
NCT01208376
Start Date
October 1 2010
End Date
August 1 2018
Last Update
December 20 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zurich
Zurich, Switzerland